Core Viewpoint - Yonghe Fluid Intelligent Control Co., Ltd. (Yonghe Intelligent Control) is undergoing a significant change in control as its controlling shareholder, Cao Delin, has signed a share transfer agreement with Hangzhou Runfeng Intelligent Equipment Co., Ltd. to transfer 8% of the company's shares, indicating a shift in management and potential strategic direction [2][3]. Group 1: Share Transfer and Control Change - Cao Delin plans to transfer 35,660,326 shares (8.00% of total shares) at a price of 8.9736 yuan per share, totaling approximately 320 million yuan [2]. - Following the share transfer, the controlling shareholder will change from Cao Delin to Hangzhou Runfeng, and the actual controller will change to Sun Rongxiang [3]. - The voting rights of the remaining shares held by Cao Delin and Xia Zuwang will be irrevocably entrusted to Hangzhou Runfeng for 18 months, establishing them as concerted actors during this period [3]. Group 2: Financial Performance and Losses - Yonghe Intelligent Control has reported continuous losses over the past three years, with a total loss of nearly 500 million yuan from 2022 to 2024 [4]. - The company's revenue for 2024 is projected at approximately 823 million yuan, a decrease of 13.19% from 2023, with a net loss attributable to shareholders of about 297 million yuan [5]. - The company anticipates a net loss of 53.24 million to 27.24 million yuan for the first half of 2025, primarily due to declining revenue from valve fittings and high depreciation and labor costs [5][6]. Group 3: Legal Issues - Yonghe Intelligent Control has disclosed ongoing litigation and arbitration cases with a total amount involved of 64.83 million yuan, which exceeds 10% of the company's latest audited net assets [8]. - The company is involved in multiple legal disputes, with a significant portion of the claims being against it [8]. Group 4: Diversification Efforts - Since Cao Delin became the actual controller in 2019, Yonghe Intelligent Control has attempted to diversify into the medical and photovoltaic sectors, acquiring stakes in various medical facilities [9][10][12]. - Despite these efforts, the company has faced challenges, including a significant loss in 2022, attributed to declining revenues and increased costs [13]. - The photovoltaic segment has underperformed, with revenues of less than 2 million yuan in 2024 and a negative gross margin of -3020.96% [15][16]. Group 5: New Shareholder Background - Hangzhou Runfeng, the acquiring company, was established on July 22, 2025, and has not yet engaged in any business activities related to industrial robots, despite its registered scope [17]. - The company is expected to change its business scope shortly after the share transfer [17][18].

申万宏源证券承销保荐有限责任公司 关于苏州麦迪斯顿医疗科技股份有限公司 保荐工作总结报告书 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"、 "保 荐机构"）作为苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"或"麦 迪科技"）2022年非公开发行股票的保荐机构，持续督导期间为2023年1月3日至 券发行上市保荐业务管理办法》、《上海证券交易所上市公司自律监管指引第11 号——持续督导》、 《上海证券交易所股票上市规则》等相关法律法规文件要求， 申万宏源承销保荐现出具保荐工作总结报告书，具体内容如下： 一、保荐机构及保荐代表人承诺 误导性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承 担法律责任。 进行的任何质询和调查。 理办法》及上海证券交易所（以下简称"上交所"）按照《上海证券交易所上市公 司自律监管指引第11号——持续督导》等有关规定采取的监管措施。 二、保荐机构基本情况 保荐机构名称 申万宏源证券承销保荐有限责任公司 新疆乌鲁木齐市高新区（新市区）北京南路358号大 注册地址 | | 成国际大厦20楼2004室 | | --- | --- | | 法定代表人 | 王 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [4][7]. Core Views - The company reported a significant decline in revenue and net profit for 2024, with total revenue at 9.952 billion yuan, down 44.66% year-on-year, and a net loss of 591 million yuan [1][4]. - Despite the challenging market conditions, the company achieved a notable increase in N-type battery shipments, with a total of 33.74 GW shipped in 2024, representing a year-on-year growth of 12.62%, and N-type battery shipments alone reached 30.99 GW, up 50.58% year-on-year [2][4]. - The company is actively expanding its overseas business, with overseas sales accounting for 23.85% of total sales in 2024, an increase of 19.16 percentage points compared to 2023 [2][4]. Summary by Sections Financial Performance - In Q4 2024, the company reported revenue of 1.750 billion yuan, a decrease of 59.08% year-on-year, and a net loss of 174 million yuan [1]. - The company expects revenues to recover in the coming years, projecting revenues of 14.807 billion yuan, 18.741 billion yuan, and 21.849 billion yuan for 2025, 2026, and 2027 respectively [4][6]. Production Capacity and Technology - The company has two major production bases for N-type batteries, achieving a total production capacity of 44 GW in 2024 [2]. - The average production efficiency of batteries has improved, with non-silicon costs reduced by 30%, and the introduction of the new N-type battery series "MoNo 2" [3]. Market Position and Outlook - The company ranks third globally in battery shipments, maintaining a leading position in N-type product shipments [2]. - The report anticipates a recovery in profitability and revenue growth as industry supply and demand improve, with projected net profits of 898 million yuan, 1.662 billion yuan, and 2.109 billion yuan for 2025, 2026, and 2027 respectively [4][6].